An American Journal of Managed Care® Supplement Hyperlipidemia: Effective Disease Management to Decrease Economic and Quality of Life Burden

Release Date: March 10, 2021
Expiration Date: March 10, 2022

Activity Overview

Recently, significant reductions were made to align the PCSK9 inhibitors with cost-effectiveness parameters. However, despite the pricing of PCSK9 agents becoming more in line with cost-effectiveness criteria, significant barriers to physician prescribing, payer approval, and patient adherence still exist. The barriers for PCSK9 inhibitor use were insurer processes, provider documentation, and administrative burden. This activity will help managed care professionals become more aware of the prevalence of hyperlipidemia and opportunities to optimize care of patients with elevated cholesterol using a more aggressive treatment approach. Managed care professionals need to understand how management of hypercholesterolemia in cardiovascular disease can prevent cardiac complications later and develop managed care protocols to support the use of effective treatment that reflects recent revisions to the most used treatment guideline.

Acknowledgement of Commercial Support

This activity is supported by educational funding provided by Amgen.

Target Audience

This activity is intended for managed care payers, pharmacy directors, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional interested in the prevalence of hyperlipidemia and opportunities to optimize care of patients with elevated cholesterol using a more aggressive treatment approach.

Pharmacists and those seeking pharmacy credits are encouraged to register with our partner, Pharmacy Times Continuing Education (https://www.pharmacytimes.org/) for the online version of this supplement at: https://www.pharmacytimes.org/on-demand/hyperlipidemia-effective-disease-management-to-decrease-economic-and-quality-of-life-burden

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the prevalence of patients who present with hyperlipidemia and quality-of-life challenges.
• Identify guideline recommendations, updates in clinical data, and new and emerging PCSK9 inhibitors.
• Examine healthcare costs associated with hyperlipidemia.
• Explore strategies that support current best practices and new therapies to help mitigate healthcare utilization costs associated with disease progression and poor treatment response.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Disclosures: Paul B. Shaw, PharmD, BCPS, BCCP, has no relevant financial relationships with commercial interests to disclose.

Disclosures: John Lindsley, PharmD, BCPS, has no relevant financial relationships with commercial interests to disclose.

Disclosures: Jeenal Patel, PharmD, BCGP, has no relevant financial relationships with commercial interests to disclose.

Medical Writing & Editorial Support

Disclosures: Lori Uildriks, PharmD, BCPS, BCGP, has no relevant financial relationships with commercial interests to disclose.

Disclosures: Jeannette Y. Wick, RPh, MBA, FASCP, has no relevant financial relationships with commercial interests to disclose.

Disclosures: Andrew Abe, PharmD, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kimberly Simpson, PharmD; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy

According to the disclosure policy of The American Journal of Managed Care^® and Pharmacy Times Continuing Education™, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of Pharmacy Times Continuing Education™ to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Disclosure of Unapproved/Off-Label Use

The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and they are advised to consult prescribing information for these products.

The information provided in this CE activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The American Journal of Managed Care^®, Pharmacy Times Continuing Education™, or any of the companies that provided commercial support for this CE activity.

Signed disclosures are on file at the office of The American Journal of Managed Care^®, Cranbury, New Jersey.

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.